AdvaMed and Georgia Bio Send Letter to Natural Resources & Environment Committee Related to Ethylene Oxide

On behalf of the Advanced Medical Technology Association (AdvaMed) and Georgia Bio, we wrote to the Natural Resources & Environment Committee to share our comments on Senate Bill 426, being considered by the legislature, related to ethylene oxide. As you may know, billions of medical devices each year in the U.S. are sterilized using ethylene oxide. The direct impact of severe restriction on the ability to sterilize medical devices could compromise the medical device industry’s ability to provide a consistent, stable, and safe supply of medical supplies to patients nationwide during the COVID-19 pandemic.

As the threat of antimicrobial resistance to disease-causing, mutating microbes continues to rise in the U.S. and around the globe, now more than ever, we need to ensure the medical and surgical equipment health care providers use is sterile. Ethylene oxide allows sterile surgeries to happen.

Please click here to view the full letter to the committee.

Georgia General Assembly Establishes Life Sciences Caucus to Advance Innovation and Industry Growth

March 17, 2026
Georgia Life Sciences leads effort to establish bipartisan caucus focused on advancing the state’s growing life sciences economy

Education And Opportunity Mark Strength Of Atlanta Biotech Industry

March 13, 2026
A skilled workforce is the engine that will drive growth across America’s biotechnology industry, and Atlanta has built multi-faceted training programs that are developing and sustaining the talent pipeline for everything from advanced laboratory research to industrial biomanufacturing.

Growing Georgia Biomanufacturing Industry Transforming American Industrial Strength

March 12, 2026
On March 12, 2026, Augusta, Georgia served as the setting for an important conversation about the future of American biotechnology and manufacturing. Manus welcomed members of the U.S. National Security Commission on Emerging Biotechnology (NSCEB) to its Augusta BioFacility to highlight how advanced biomanufacturing is strengthening U.S. supply chain resilience and supporting the growing bioeconomy. During the visit, Manus unveiled a significant expansion of its 44-acre Augusta BioFacility, increasing domestic capacity to produce critical biobased ingredients. The expansion further positions Georgia as a key hub for advanced biomanufacturing and demonstrates the growing role of biotechnology in strengthening national economic and supply chain security. Commission members met with leaders from industry, government, and academia to discuss strategies for scaling manufacturing infrastructure, strengthening resilient supply chains, and preparing the workforce needed to support the next generation of the U.S. bioeconomy. The visit also included conversations with Manus employees about the practical realities of building and operating advanced biomanufacturing facilities in the United States. The Augusta site has become one of the largest advanced biomanufacturing facilities in the country, producing a growing portfolio of bioalternatives at industrial scale. Among these products is high-purity Reb M, recently launched as Yume™ M Stevia Sweetener , supported by an all-Americas supply chain. “As we scale the Manus bioalternatives platform, Augusta has become a powerful example of what the modern U.S. bioeconomy looks like in practice,” said Manus Founder and CEO Ajikumar Parayil. The visit underscores Georgia’s expanding leadership in life sciences manufacturing and highlights how regional ecosystems can help advance U.S. leadership in biotechnology and biomanufacturing. Learn more about the expansion and visit: Manus welcomes U.S. National Security Commission on Emerging Biotechnology to unveil major Augusta BioFacility expansion Growing Georgia Biomanufacturing Industry Transforming American Industrial Strength
MORE POSTS